Global approach to cardiovascular risk in chronic kidney disease: Reality and opportunities for intervention  by De Nicola, L. et al.
Global approach to cardiovascular risk in chronic
kidney disease: Reality and opportunities
for intervention
L De Nicola1, R Minutolo1, P Chiodini1, C Zoccali2, P Castellino3, C Donadio4, M Strippoli5, F Casino6,
M Giannattasio7, F Petrarulo5, M Virgilio8, E Laraia5, BR Di Iorio9, V Savica10 and G Conte1, on behalf
of the TArget Blood Pressure LEvels in Chronic Kidney Disease (TABLE in CKD) Study Group11
1Chair of Nephrology, Department of Medicine and Public-Health Research Center for Cardiovascular Disease, Second University of
Napoli, Napoli, Italy; 2Division of Nephrology, Consiglio Nazionale della Ricerca in Reggio Calabria, Italy; 3Division of Nephrology,
University of Catania, Italy; 4Division of Nephrology, University of Pisa, Italy; 5Division of Nephrology, University/Hospital Di Venere and
S Rita, Bari, Italy; 6Division of Nephrology, Hospital, Matera, Italy; 7Division of Nephrology, Hospital, Putignano, Italy; 8Division of
Nephrology, Hospital, Molfetta, Italy; 9Division of Nephrology, Hospital, Solofra, Italy and 10Division of Nephrology, Hospital,
Messina, Italy
The current implementation into nephrology clinical practice
of guidelines on treatment of cardiovascular (CV) risk factors
in chronic kidney disease (CKD) is unknown. We designed
a cross-sectional analysis to evaluate the prevalence and
treatment of eight modifiable CV risk factors in 1058
predialysis CKD patients (stage 3: n¼ 486; stage 4: n¼ 430,
stage 5: n¼ 142) followed for at least 1 year in 26 Italian renal
clinics. The median nephrology follow-up was 37 months
(range: 12–391 months). From stages 3 to 5, hypertension
was the main complication (89, 87, and 87%), whereas
smoking, high calcium-phosphate product and malnutrition
were uncommon. The prevalence of proteinuria (25, 38,
and 58%), anemia (16, 32, and 51%) and left ventricular
hypertrophy (51, 55, and 64%) significantly increased, while
hypercholesterolemia was less frequent in stage 5 (49%) than
in stages 4 and 3 (59%). The vast majority of patients
received multidrug antihypertensive therapy including
inhibitors of renin–angiotensin system; conversely,
diuretic treatment was consistently inadequate for both
frequency and dose despite scarce implementation of
low salt diet (19%). Statins were not prescribed in most
hypercholesterolemics (78%), and epoietin treatment was
largely overlooked in anemics (78%). The adjusted risk for
having a higher number of uncontrolled risk factors rose in
the presence of diabetes (odds ratio 1.29, 95% confidence
interval 1.00–1.66), history of CV disease (odds ratio 1.48, 95%
confidence interval 1.15–1.90) and CKD stages 4 and 5
(odds ratio 1.75, 95% confidence interval 1.37–2.22 and odds
ratio 2.85, 95% confidence interval 2.01–4.04, respectively).
In the tertiary care of CKD, treatment of hypertension is
largely inadequate, whereas therapy of anemia and
dyslipidemia is frequently omitted. The risk of not achieving
therapeutic targets is higher in patients with diabetes, CV
disease and more advanced CKD.
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Prevention of cardiovascular (CV) disease is now recognized
as the main goal of conservative treatment of chronic kidney
disease (CKD).1 In CKD patients, CV risk rises proportio-
nally to the decline of renal function and becomes remarkable
when glomerular filtration rate (GFR) is below 60 ml/min/
1.73 m2.2,3 The impact of CV complications is so important
that the risk for fatal and nonfatal CV events overcomes that
for renal disease progression; the mortality rate, in fact, has
been found up to eightfold greater than that of renal
replacement therapy.2,3 These data are consistent with the
observation that in CKD, at variance with general popu-
lation, the age-adjusted death rates have not declined in the
last two decades.4
Several modifiable determinants of CV risk have been
identified in these patients, the main being hypertension,
hypercholesterolemia, left ventricular hypertrophy (LVH),
smoking, anemia, abnormal calcium-phosphate (Ca-P)
metabolism, proteinuria and malnutrition.1 Furthermore,
the International Guidelines on prevention of CV disease
have repeatedly recommended intensive treatment of the
main CV risk factors in CKD population since 1997–1998.5–10
These recommendations have been reiterated in 1999 also by
the Italian Society of Nephrology, which issued guidelines on
this topic that circulated amply and in various formats
among the Italian nephrology community.11
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To efficaciously prevent CV disease in CKD patients, the
preliminary knowledge of the prevalence and management of
CV risk factors is required.4 Indeed, observational studies are
now considered as essential tools to verify whether efficacy of
specific interventions, proven in the experimental setting of
randomized trials and diffused by means of guidelines,
translates into effective treatment in routine practice.12 To
date, however, the degree of implementation into clinical
practice of the recommendations on treatment of CV risk
factors in CKD is still unknown. The information provided
by the few observational studies on the care of these patients,
in fact, is largely inadequate because of small sample size,
limited assessment of risk factors and outdated data
collection, that is, performed when therapeutic targets were
less restrictive.13–17 Furthermore, in the previous studies,
patient population was heterogeneous for type of care
provider and the examined patients were generally incident.
On the contrary, to the best analysis of management and,
consequently, to identify the main areas of intervention, it
is essential to evaluate the global approach to CV risk in
patients followed for an adequate period in the nephrology
setting, that is, the reference of care for CKD patients.
This multicentric cross-sectional study was aimed at
evaluating treatment and prevalence of the main modifiable
determinants of CV risk in patients with CKD stages 3–5
followed for at least 1 year in Italian nephrology clinics.
RESULTS
Overall, 1353 consecutive patients with CKD stages 3–5,
followed for at least 1 year in the 26 participating renal
clinics, were screened. We did not enrol 295 patients on the
basis of exclusion criteria or lack of information at the time
of study visit; therefore, 1058 patients were included in the
final analysis and divided in the three GFR categories (stage
3: n¼ 486, 46%; stage 4: n¼ 430, 41%; stage 5: n¼ 142,
13%). The median follow-up in the nephrology referral
centers was 37 months (range: 12–391 months) with no
difference in the three stages.
Table 1 depicts the main clinical characteristics of the
study subjects. More advanced disease was coupled with
greater prevalence of female and diabetic patients, although
no relevant difference was detected in age, body mass index,
blood pressure (BP) values and prevalence of CV disease. The
causes of CKD were equally distributed in the three stages
with the exception of diabetic nephropathy that was less
prevalent in patients with mild CKD. Of note, the prevalence
of patients with CKD secondary to diabetes was largely
inferior to that of diabetic patients.
The laboratory data collected at study visit are reported in
Table 2. Creatinine clearance overestimated GFR. This
finding was confirmed by regression analysis and Bland–Alt-
man plot (Figure 1), with a difference between the two
methods (3.6 ml/min/1.73 m2 on average) that increased with
the increment of GFR. As depicted in Table 2, more severe
disease was associated with decreasing levels of serum
cholesterol, hemoglobin and Ca, whereas proteinuria, serum
P and Ca-P product progressively increased from stage 3 to 5.
Table 1 | Clinical characteristics of patients in the three stages of CKD
Stage 3 (n=486) Stage 4 (n=430) Stage 5 (n=142) P-value
Age (years) 66714 67714 65714 0.248
Male sex (%) 313 (64.4) 218 (50.7) 64 (45.1) o0.0001
Body mass index (kg/m2) 27.074.1 27.274.7 26.874.7 0.673
Diabetes (%) 113 (23.2) 121 (28.1) 47 (33.1) 0.011
Systolic BP (mmHg) 138717 141719 140719 0.292
Diastolic BP (mmHg) 81710 81711 8079 0.991
CVD (%) 139 (28.6) 133 (30.9) 42 (29.6) 0.665
Renal disease (%)
Diabetes 39 (8.0) 65 (15.1) 22 (15.4)
Hypertension 123 (25.3) 90 (20.9) 29 (20.4)
GN/IN/PKD 145 (29.8) 122 (28.4) 48 (33.8)
Other 179 (36.8) 153 (35.6) 43 (30.3)
BP=blood pressure; CKD=chronic kidney disease; CVD=cardiovascular disease defined as history of coronary, cerebrovascular or peripheral vascular disease or congestive
heart failure; GN=glomerulonephritis; IN=interstitial nephritis; PKD=polycystic kidney disease.
Quantitative variables are reported as mean and standard deviation, categorical variables as absolute numbers and percentages (%).
Table 2 | Laboratory characteristics of patients in the three
stages of CKD
Stage 3
(n=486)
Stage 4
(n=430)
Stage 5
(n=142) P-value
Total cholesterol (mg/dl) 200740 201744 188745 0.004
Hemoglobin (g/dl) 13.171.8 12.171.7 11.471.5 o0.0001
Serum creatinine (mg/dl) 1.670.3 2.870.6 5.171.3 o0.0001
eGFR (ml/min/1.73 m2) 42.178.1 22.274.2 11.272.5 o0.0001
CrCl (ml/min/1.73 m2) 45.2712.5 26.478.4 13.974.5 o0.0001
Serum P (mg/dl) 3.670.8 4.070.8 4.571.0 o0.0001
Serum Ca (mg/dl) 9.470.7 9.270.7 9.170.8 o0.0001
Ca-P product (mg2/dl2) 3478 3778 4079 o0.0001
Albumin (g/dl) 3.970.5 3.970.5 3.970.5 0.600
Proteinuria (g/24 h) 0.8371.33 1.1271.39 1.7671.99 o0.0001
UNaV (mmol/24 h) 154756 149758 148754 0.357
UUN (g/24 h) 7.473.3 6.573.1 5.672.8 o0.0001
Ca-P=calcium-phosphate; CKD=chronic kidney disease; CrCl=creatinine clearance
measured from 24-h urine collection; eGFR=GFR value estimated by MDRD
equation; UNaV=urinary sodium excretion; UUN=urinary urea nitrogen.
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Analysis of 24-h urine collection revealed that only 19% of
patients had, on average, a sodium intake p100 mmol/24 h,
with no difference in the three stages (16, 22, and 16%,
P¼ 0.40). Protein intake (g/kg body wt/day) decreased with
GFR decline, being 0.8570.31 in stage 3, 0.7870.27 in stage
4 and 0.6970.26 in stage 5 (Po0.0001).
Figure 2 depicts the distribution of uncontrolled CV risk
factors in the three CKD stages examined. The prevalence of
anemia, LVH and proteinuria progressively rose from stages 3
to 5, whereas hypercholesterolemia was less frequent in stage
5. In particular, 58% of the whole group of patients had
cholesterol levels 4190 mg/dl, with a distribution in the
three stages that was similar to that of low-density
lipoprotein 4100 mg/dl (analysis available in 612/1058
subjects). Poor hypertension control represented the main
complication, with only 12.0% (95% confidence interval
10.0–14.0) of patients showing BP valueso130/80 mmHg; in
particular, 21.6% (95% confidence interval 19.1–24.0) of
patients reached the target for systolic BP, whereas isolated
diastolic BP target was detected in 28.8% (95% confidence
interval 26.1–31.6) of subjects. Of note, the majority of
patients (61%) did not even reach the less restrictive goal of
140/90 mmHg indicated for patients with essential hyperten-
sion and normal renal function. The weight of this CV risk
factor is also evidenced by the prolonged exposition of
patients to this complication; median duration of hyper-
tension, in fact, was 76 months (range: 3–511 months), with
no difference in the three stages. Conversely, a negligible
prevalence was found for the other examined CV risk factors,
such as smoking and abnormal Ca-P metabolism. Also,
malnutrition, defined by the concomitant presence of serum
albumin o3.5 g/dl and body mass index o20 kg/m2, was
rare; on the contrary, isolated hypoalbuminemia was detected
in 14.8% of patients. On average, the number of uncontrolled
modifiable CV risk factors per patient significantly increased
from stages 3 to 5 (2.471.0, 2.771.0, 3.071.2, Po0.0001),
although it was not influenced by the type of referral center
(P¼ 0.481).
As depicted in Table 3, the number of uncontrolled risk
factors became larger in the presence of diabetes, history of
CV disease and with worsening of renal function, although it
was not affected by age, gender and duration of renal disease.
This association was confirmed by multivariate analysis
shown in Table 4. Specifically, the risk of having an increased
number of uncontrolled CV risk factors was significantly
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Figure 1 | Comparison between CrCl measured from 24-h urine
collection (CrCl, ml/min/1.73 m2) and GFR estimated by
Modification of Diet in Renal Disease equation (eGFR, ml/min/
1.73 m2). The graph on the left represents the regression statistics:
CrCl is indicated on the Y-axis and eGFR on the X-axis; line represents
the linear regression and r indicates the linear correlation coefficient
with the values of the 95% interval of confidence in parenthesis. The
graph on the right is the Bland–Altman plot: mean and difference of
the two measures are the X- and Y-axis, respectively; the solid line
represents the mean of the differences between the two values for
each individual, whereas the upper and lower dotted lines indicate
the 95% distribution of the difference.
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Figure 2 | Prevalence of uncontrolled cardiovascular risk factors
in CKD stages 3 (white bars), 4 (dotted bars) and 5 (gray bars),
and 95% confidence interval. See Materials and Methods for
definition of risk factors. w2 for trend: P¼ 0.56 for hypertension,
Po0.0001 for anemia, P¼ 0.01 for LVH, Po0.0001 for proteinuria,
P¼ 0.10 for high-chol, P¼ 0.20 for smoking, P¼ 0.13 for CaxP and
P¼ 0.11 for malnutrition.
Table 3 | Characteristics of CKD patients grouped by number of uncontrolled cardiovascular risk factors
0–1 (n=148) 2 (n=375) 3 (n=347) X4 (n=188)
Age (years) 65715 66714 67714 65715
Male sex (%) 86 (58.1) 206 (54.9) 192 (55.3) 111 (59.0)
Body mass index (kg/m2) 27.574.8 26.774.2 27.474.4 26.774.5
Diabetes (%)* 35 (23.8) 87 (23.2) 93 (26.8) 66 (35.1)
Serum creatinine (mg/dl)* 2.271.1 2.471.1 2.671.2 3.271.6
eGFR (ml/min/1.73m2)* 35713 32714 29713 24712
Duration of renal disease (months) 73773 67759 65753 69761
CVD (%)* 41 (27.7) 82 (21.9) 128 (36.9) 64 (34.0)
CKD=chronic kidney disease; CVD=cardiovascular disease defined as history of coronary, cerebrovascular or peripheral vascular disease or congestive heart failure; eGFR=GFR
value estimated by MDRD equation.
Quantitative variables are reported as mean and standard deviation, and categorical variables as absolute numbers and percentages (%).
*Po0.01.
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higher in diabetic patients, in patients with established CV
disease and in patients with more advanced CKD. Test of the
proportional odds assumption was not significant, indicating
that the proportional odds model was appropriate for these
data and separate binary logistic regression analyses yielded
to odds ratios comparable to those reported in Table 4 (data
not shown). The modified Pearson’s w2 test revealed good fit
of the model with values of 139.7 (df¼ 136, P¼ 0.40). As the
first-order interactions were not statistically significant, they
were not entered into the final model. The lack of significant
interaction supports the multiplicative effect of the odds
ratios estimated by the model. Therefore, we could estimate
the global risk by multiplying the respective odds ratios,
meaning that the risk resulted more than three- and fivefold
greater in patients with diabetes, CV disease and CKD stages
4 and 5, respectively, than with patients with CKD stage 3 and
neither diabetes nor CV disease.
The therapeutic approach to the main modifiable CV risk
factors by CKD stage is depicted in Table 5. The vast majority
of patients showed BP levels above target despite treatment,
whereas only 3.7% of patients with uncontrolled BP was left
untreated. Treatment modality changed when considering the
other two main CV risk factors. Indeed, most anemic and
hypercholesterolemic patients did not receive any treatment.
Specifically, epoietin treatment was omitted in the majority
of anemic patients (stages 3–5: 89, 77, and 67%), and statin
therapy was not prescribed in most hypercholesterolemic
patients (stages 3–5: 77, 78, and 81%).
Other cardioprotective medications, such as anti-aggre-
gant agents, nitroderivates and digitalis-like drugs, were
overall similarly prescribed from stages 3 to 5 (17, 19, and
21%, P¼ 0.19).
As hypertension was the main modifiable CV risk factor in
the population studied, a detailed analysis of antihypertensive
therapy was performed (Table 6). From stages 3 to 5, the
number of prescribed drugs per patient only increased
slightly (2.071.0, 2.271.1, and 2.171.1%, P¼ 0.016). The
majority of hypertensive patients received at least two drugs
(stages 3–5: 68, 74, and 74%, P¼ 0.043). Most patients were
treated with inhibitors of activity of renin–angiotensin
system; the prescriptions of converting enzyme inhibitors
overcame those of angiotensin II receptor blockers. The
prescription of renin–angiotensin system inhibitors signifi-
cantly decreased from stages 3 to 5, whereas that of calcium
channel blockers and b-blockers slightly increased. Furose-
mide, that is the loop diuretic almost exclusively used, was
the third drug after renin–angiotensin system inhibitors and
calcium channel blockers. This drug was given to a minority
of hypertensive patients, and in more than 50% of these
cases, the prescribed dose resulted inappropriately low for the
degree of GFR impairment.
DISCUSSION
The novel finding of this study is that despite the wide
diffusion of guidelines, recognized CV risk factors are poorly
Table 4 | Adjusted odds ratios relating to the number of
uncontrolled modifiable cardiovascular risk factors to age,
gender, diabetes, cardiovascular disease and CKD stage
Variable Odds ratio 95% CI P-value
Age (10 years) 0.96 0.88–1.04 0.293
Gender (male vs female) 1.13 0.90–1.41 0.305
Diabetes (yes vs no) 1.29 1.00–1.66 0.049
CVD (yes vs no) 1.48 1.15–1.90 0.002
CKD stage o0.0001
4 vs 3 1.75 1.37–2.22
5 vs 3 2.85 2.01–4.04
CKD=chronic kidney disease; CVD=cardiovascular disease defined as history of
coronary, cerebrovascular or peripheral vascular disease or congestive heart failure.
Table 5 | Treatment and control rates of the main modifiable
cardiovascular risk factors in CKD stage 3 (n=486), stage 4
(n=430), and stage 5 (n=142)
Target reached Target not reached
Treated Untreated Treated Untreated
Hypertension
Stage 3 46 (9.5) 9 (1.9) 415 (85.4) 16 (3.3)
Stage 4 52 (12.0) 2 (0.5) 364 (84.7) 12 (2.8)
Stage 5 16 (11.3) 2 (1.4) 113 (79.6) 11 (7.7)
Overall 114 (10.8) 13 (1.2) 892 (84.3) 39 (3.7)
Anemia
Stage 3 3 (0.6) 407 (83.7) 8 (1.6) 68 (14.0)
Stage 4 31 (7.2) 260 (60.5) 32 (7.4) 107 (24.9)
Stage 5 25 (17.6) 45 (31.7) 24 (16.9) 48 (33.8)
Overall 59 (5.6) 712 (67.3) 64 (6.0) 223 (21.1)
Hypercholesterolemia
Stage 3 40 (8.2) 158 (32.5) 65 (13.4) 223 (45.9)
Stage 4 38 (8.8) 137 (31.9) 56 (13.0) 199 (46.3)
Stage 5 10 (7.0) 62 (43.7) 13 (9.2) 57 (40.1)
Overall 88 (8.3) 357 (33.7) 134 (12.7) 479 (45.3)
CKD=chronic kidney disease.
Data are expressed as the number and % of patients. Target values are defined as
following: blood pressure o130/80 mmHg, hemoglobin X11 g/dl (female) and
12 g/dl (male) and serum total cholesterol p190 mg/dl.
Table 6 | Classes of antihypertensive drugs in the three stages
of CKD
Stage 3
(n=486)
Stage 4
(n=430)
Stage 5
(n=142)
CEI 58 56 40
ARB 21 24 18
CEI+ARB 5 4 4
CCB 46 46 50
Furosemide 27 42 51
Dosage (mg/day)a 41750 55750 85783b
Dosage p25 mg/day 69 46 31b
Thiazides 9 7 1
BB 16 17 22
Other 22 29 31
ARB=angiotensin receptor blocker; BB=beta-blockers; CCB=calcium channel
blockers; CEI=converting enzyme inhibitors; CKD=chronic kidney disease.
Data are expressed as % of treated patients.
aMean7standard deviation.
bPo0.0001 for trend.
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controlled in most CKD patients regularly followed by
nephrologist. Furthermore, this study identifies, for the first
time, the predictors of control of the main modifiable
determinants of CV risk and the major areas of improvement
as well. An additional strength of the study is the
stratification of patients by CKD stage. In this regard, it is
important to note that we provide evidence from Italian
patients of the tendency of 24-h creatinine clearance to
overestimate kidney function, as previously shown in the US
patients,18 especially for higher GFRs (Figure 1).
The population examined in this study was characterized
by a high prevalence of advanced age and diabetes, and one
patient out of three, moreover, had at least one CV event in
his clinical history. In the presence of this unmodifiable CV
risk, most of the main modifiable factors resulted insuffi-
ciently controlled (Figure 2). Only 12% of patients had their
BP controlled to less than 130/80 mmHg. A recent analysis of
the Fourth National Health and Nutrition Survey has shown
a BP control rate of 37% in a sample of CKD patients living
in the US;19 that survey, however, is not comparable with the
current study as definition of BP target was less restrictive,
entity of renal dysfunction was minor and the methodology
used to measure BP was different.
We also detected hypercholesterolemia in 50–60% of
patients throughout the three stages; the prevalence of
anemia, proteinuria and LVH rose proportionally to GFR
decline reaching a value greater than 50% in stage 5. The
prevalence of smoking habit and elevated Ca-P product was
irrelevant. Also malnourished patients were rare. In contrast,
patients with hypoalbuminemia and normal body mass index
represented about 15% of the population examined. Previous
studies have suggested an independent association between
hypoalbuminemia and inflammation/comorbidities in this
subgroup of patients.20,21
This study likely underestimates the true dimension of the
‘undertreatment’ problem in CKD patients; we in fact studied
patients with prolonged follow-up in nephrology centers,
whereas control of complications is certainly worse in
unreferred patients.22,23 Indeed, there is large consensus that
early referral of CKD patients to nephrologist is highly
desirable.8 These considerations should therefore induce
nephrologists at optimizing the conservative care of CKD.
The majority of patients received multidrug antihyper-
tensive therapy including renin–angiotensin system inhibitors.
This is the most important point of adherence to the current
guidelines on CKD care and, at the same time, it represents a
main difference with previous studies that showed BP levels
generally greater than 140/90 mmHg in the presence of a
minor use of these agents.13,15 While it is not possible to
exclude that further increases in the number of antihyper-
tensive agents may be useful, the present analysis evidences
an inadequate therapeutic approach to the extracellular
volume expansion, which is a key determinant of CKD-
related hypertension.24–26 More than 80% of patients showed
excessive salt intake. This critical information is original as no
survey on hypertension control in CKD has evaluated salt
intake by measuring 24-h urinary sodium excretion.
Furthermore, a loop diuretic was given to only a limited
number of patients, and frequently at a dose inappropriately
low for the degree of renal dysfunction. In this regard, it is
remarkable that the dose of furosemide was stillp25 mg/day
in one-third of patients with eGFR (GFR estimated by
Modification of Diet in Renal Disease equation)o15 ml/min.
Conversely, in a small previous intervention trial by our
group, effective salt restriction decreased per se mean arterial
pressure of as much as 10 mmHg in patients with moderate
to advanced CKD.27 Similarly, therapy with loop diuretics at
high dose has been found efficacious in reaching and
maintaining low BP levels.24,25 Indeed, uptitration of loop
diuretic dosage is required in CKD because of the reduced
number of functioning nephrons, lower renal blood flow,
accumulation of organic acids and proteinuria.26 These data,
therefore, identify the treatment of volume expansion as a
major area of improvement in the conservative care of CKD
patients. It is important to note, however, that renin–angio-
tensin system inhibition was only apparently optimal; in fact,
we found an extremely low rate of prescriptions of
combination therapy with converting enzyme inhibitors
and angiotensin II receptor blockers despite the large
evidence of the major renoprotective efficacy, in the absence
of significant side effects, of this intervention.28
At variance with hypertension, the other two main
modifiable CV risk factors, such as anemia and hypercholes-
terolemia, resulted inadequately controlled mainly because of
omitted rather than insufficient therapy. Within the anemic
subgroup of the population examined, in fact, 64% did not
receive epoietin, whereas only 18% resulted undertreated.
Conversely, about 50% of treated patients reached the
hemoglobin target. Therefore, these data suggest that, at
odds with therapy of hypertension whose target was reached
in 12% of treated patients, hemoglobin goal can be more
easily achieved when therapy is started. Furthermore,
omission of therapy involved a relatively higher fraction of
anemic patients with mild to moderate CKD probably
because of greater underestimation of the problem in the
initial phases of disease. This point is not trivial; recent
studies, in fact, have revealed beneficial effects of epoietin on
both CV disease and progression of renal disease when
treatment is established early.29–31 Nevertheless, we noted
only a slight improvement in epoietin prescription with
respect to previous surveys.13,14,31,32 These early studies, in
fact, showed a maximal treatment rate of 16–27% in
advanced CKD, whereas in our stage 5 patients, epoietin
was prescribed in 35% of cases. The increasing omission of
intervention on anemia from stages 3 to 5 likely accounted,
together with the poor BP control, for the parallel increment
detected in the prevalence of LVH. In this regard, it is
important to underline that a recent pooled analysis has
demonstrated that LVH is an independent risk factor for CV
disease from the earlier stages of CKD, and that patients who
have both LVH and anemia are at particularly increased
risk.33 Similarly to anemia, we observed a pervasive lack of
542 Kidney International (2006) 69, 538–545
o r i g i n a l a r t i c l e L De Nicola et al.: Management of cardiovascular risk in CKD
intervention on hypercholesterolemia. Indeed, despite statin
prescription in our cohort was double than that reported in
the past,14,15 the vast majority of hypercholesterolemic
patients was still left untreated. Again, this observation
becomes crucial when considering the positive CV and renal
effects of statins in CKD.34,35
At variance with pharmacological interventions, a parti-
cular attention was dedicated to the nutritional care of
patients. Dietary protein intake was on average adherent to
the levels recommended by the guidelines,8,11 and, conse-
quently, hyperphosphatemia was absent in virtually all
patients. As in the case of 24-h urinary sodium excretion,
this finding is original as no survey in CKD has evaluated the
current recommendations on protein intake by measuring
24-h urinary excretion of urea.
This study, which was meant to represent clinical practice,
has the limitation of evaluating prescription rather than
adherence to therapy. However, this potential bias becomes
irrelevant when considering that the prescribed therapy was
per se inadequate. Therefore, this study discloses a ‘clinical
inertia’ in this high-risk population. In particular, the adjusted
risk of a worse management of CV risk factors was 75 and
185% greater in stages 4 and 5 than in stage 3, and the
presence of diabetes or CVD increased the risk by 29 and
48%, whereas the simultaneous presence of diabetes, CVD
and more advanced CKD maximized the risk of being
undertreated. These data indicate that nephrologists do not
properly intensify therapy when the CV burden increases in
parallel with worsening of disease. Similar data have also been
collected in settings other than nephrology. In particular,
coronary heart disease has been found insufficiently treated in
CKD patients;36–39 such an erroneous attitude is not justifiable
anymore as ischemic CV disease results ‘normally’ responsive
to treatment throughout the entire spectrum of CKD.37–39
An additional finding of this survey is the gross disparity
between the prevalence of diabetes and diabetic nephropathy.
The relatively lower number of patients with diabetic
nephropathy was likely owing to the strict criteria adopted
here to identify them and, consequently, to limit diabetic
nephropathy misclassification, which is a critical problem
raised in the US as in European countries.40
In conclusion, this systematic analysis evidences that in
patients with CKD stages 3–5 regularly followed in the
nephrology care setting: (a) treatment of the main modifiable
CV risk factors is far to be optimal, (b) while hypertension is
undertreated possibly because of inadequate approach to
extracellular volume expansion, therapy of anemia and
hypercholesterolemia is frequently omitted and (c) patients
with a combination of diabetes, established CVD and
advanced renal disease carry the greatest risk for not
achieving the therapeutic targets. These findings call for
action; the pervasive lack of intervention on these risk factors
may, in fact, greatly contribute to the high CV risk. This
hypothesis is substantiated by recent studies showing that in
CKD, the main modifiable CV risk factors have larger
association with CV mortality than novel risk factors.41–43
MATERIALS AND METHODS
This is a multicentric cross-sectional study of nondialyzed and
nontransplanted adult CKD patients followed on regular basis in
tertiary care. Twenty-six Italian nephrology referral centers took part
in the research program; 10 centers were in academic institutions, 15
in public hospitals and one was a clinical research unit of the Italian
National Research Council. Inclusion criteria of the centers were:
presence of outpatient clinic dedicated to the conservative care of
CKD, with attending patient population seen at least twice per year;
presence of clinical and laboratory protocols for the care of these
patients, including double measurement by physician of BP 5 min
apart in sitting position after 10 min of rest, with Korotkoff phases I
and V defining systolic BP and diastolic BP values; measurement
of creatinine in plasma and urine by means of the modified
kinetic Jaffe´ reaction; and complete blood and urine analysis
profile performed at least two times per year. The protocol was
approved by the Ethical Committee of the Second University of
Naples.
Patients
We considered eligible all the consecutive patients consulting the
centers during a 6-month period of 2003 that had diagnosis of CKD
and estimated GFRo60 ml/min/1.73 m2. We excluded patients with
changes of GFR greater than 30% in the previous 6 months. As the
aim of the current study was to study patients steadily followed by
nephrologist, we excluded patients whose first visit at the renal clinic
dated back less than 1 year.
Data collection and definitions
For each patient, information covered demographic and medical
history data, including diagnosis of diabetes mellitus, history of CV
event, defined as the presence in the patient’s history of any event
among coronary artery disease, congestive heart failure, cerebrovas-
cular and peripheral vascular disease. Diagnosis of underlying
nephropathy was also requested; in diabetic patients, diabetic
nephropathy was considered as the cause of CKD when, after
exclusion of known nondiabetic kidney disease, both albuminuria
and diabetic retinopathy were reported in the clinical history.
Clinical data, including therapy with the indication of prescribed
dose, and laboratory data were collected at the time of study visit,
which was planned in 2003. Laboratory analysis included measure-
ment of serum Na, K, and creatinine, serum total cholesterol, low-
density lipoprotein cholesterol, hemoglobin, serum albumin, serum
phosphate (P) and calcium (Ca), 24-h measured creatinine clearance
(CrCl), 24-h proteinuria, 24-h urinary sodium excretion and 24-h
urinary urea nitrogen.
The case report forms were filled in at each center, keeping
anonymous the patients’ identity, and sent to the coordinating
center at the Second University of Naples for analysis.
Twenty-four urine collection was considered inaccurate and
discarded if the value of measured creatinine excretion rate was
outside the 60–140% range of the value calculated according to
Dwyer and Kenler.44 Daily salt intake (g/day) was calculated dividing
24-h urinary sodium excretion by 17 and daily protein intake was
calculated by measuring urinary urea nitrogen.27
CKD stage was defined by the category of estimated GFR (stage 3:
GFR 30–59; stage 4: GFR 15–29; stage 5: GFR o15).8 GFR was
estimated using a formula derived by the Modification of Diet in
Renal Disease study group: estimated GFR¼ 186.3 (serum
creatinine)1.154 age0.203 (0.742 if women) (1.21, if black).18
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At the time of study visit, we assessed the prevalence of eight
modifiable CV risk factors. These factors were defined as uncon-
trolled according to thresholds indicated by expert panels:1,5–11
hypertension (BP X130/80 mmHg), anemia (hemoglobin o11 g/dl
in women and o12 g/dl in men), LVH (detected at either
electrocardiography or echocardiography), clinically significant
proteinuria (protein excretion 41.0 g/24 h), high cholesterol levels
(serum total cholesterol 4190 mg/dl), smoking habit (smoking in
the last 6 months), frank malnutrition (serum albumin o3.5 g/dl
and body mass index o20 kg/m2) and abnormal Ca-P metabolism
(Ca-P product 455 mg2/dl2).
Statistical analysis
Data were analyzed using SAS version 8.1 (SAS Inc., Cary, NC, USA).
We report quantitative variables as mean and standard deviation,
and categorical variables as absolute numbers and percentages (%).
Differences in clinical and laboratory characteristics of patients in
the three CKD stage were tested by means of one-way ANOVA and
w2 methods for quantitative and qualitative variables, respectively.
Agreement between estimated GFR and 24-h measured clearance
creatinine was studied first by linear regression and correlation
coefficient, and second by Bland–Altman method.45 Multivariate
analyses were performed, using ordinal logistic regression under a
proportional odds model,46 to evaluate the predictors of number of
the uncontrolled CV risk factors examined (NRF: hypertension,
anemia, LVH, high cholesterol levels, proteinuria, malnutrition,
smoking, high Ca-P product). NRF was grouped into four ordered
categories (0–1, 2, 3, andX4) owing to the low prevalence of subject
with none or more than four NRF. This approach simultaneously
models three cumulative logits that corresponds to using binary
cut points at 2, 3, and 4, written as log{Pr(NRFX2)/Pr(NRFo2)},
log{Pr(NRFX3)/Pr(NRFo3)} and log{Pr(NRF)X4/Pr(NRFo4)},
respectively. Under this proportional odds model, one coefficient is
estimated for each predictor in the model. The coefficient represents
the effect of a one-unit increase in the predictor variable on the logit
(log odds), which is assumed to be the same for all three logits. A
score test was used to verify the proportional odds assumption in the
final model.47 To further verify the proportional odds model, we fit
binary logistic regressions using NRF cutoffs of at least 2, 3, and 4,
and compared the results with those of the ordinal regressions. The
first-order interactions of the main effects of the model were tested
one by one by means of likelihood ratio test. Goodness of fit was
assessed using a method recently proposed by Pulkestenis and
Robinson based on the modified version of the Pearson w2 test that is
appropriate for assessing goodness of fit in ordinal response models
when both categorical and continuous covariates are present.48
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